We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Celgene To Pay $280M To End Off-Label Cancer Drug FCA Suit

Law360, Los Angeles (July 25, 2017, 6:12 PM EDT) -- Celgene Corp. has agreed to shell out $280 million to end a False Claims Act suit launched in California by a whistleblower who accused the drug company of promoting off-label uses...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

California Central

Nature of Suit

Other Statutory Actions

Judge

Subscribers Only

Date Filed

April 27, 2010

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.